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INTRODUCTION
                       Ageing is an inevitable process that converts young adults into older  
adults  with  deteriorating  physiological  fitness  and  progressively  increasing  risks  of 
illness and death. The ageing of the endocrine system is characterised by the progressive 
loss of reserve capacity and impaired homeostatic regulation. These changes may not be 
clinically apparent under baseline conditions and the presenting manifestations are often 
nonspecific or muted or atypical or subtle.
                       Thyroid dysfunction is among the most common endocrine disorders in  
the  elderly  second  only  to  Diabetes  mellitus.  Hypothyroidism is  the  most  frequent 
thyroid dysfunction. The clinical manifestations may be less obvious in the setting of 
somatic complaints and other conditions related to ageing. More often it is diagnosed 
biochemically on evaluation for other co-morbid illnesses rather than clinically.
                       Subclinical hypothyroidism is the most common form of hypothyroidism 
in  elderly. It  is  defined  as  a  biochemical  state  characterised  by serum  Thyroid 
Stimulating Hormone (TSH) concentration above the statistically defined upper limit of 
the  reference  range  when  serum  free  Thyroxine  (FT4)  concentration  is  within  its 
reference  range in  the  presence  of  few or no  definitive  clinical  signs  or  symptoms 
suggestive of hypothyroidism. 
                       The prevalence of subclinical hypothyroidism is age dependant. In 
geriatric populations it  has been reported to range from 5.9% to 35% depending on 
health status, patient characteristics and patient selection procedures. Older women are 
at greater risk for subclinical hypothyroidism than older men. Many studies proved that 
the prevalence of subclinical hypothyroidism was more than three fold increased in older 
women than in older men. 
                       Subclinical hypothyroidism is most commonly an early stage of overt  
hypothyroidism. Progression to overt hypothyroidism ranges from 5 to 20 percent per 
year  in  patients  with  high  titres  of  thyroid  antibody  levels  and  slightly  elevated 
Thyrotropin (TSH) levels.
                        Patients with subclinical hypothyroidism may have increased levels of  
total and LDL cholesterol atleast slightly higher than euthyroid patients. The effects of 
dyslipidemia are less pronounced than in overt disease but predispose these patients to 
the development of severe cardiac disease.
                       Cardiovascular abnormalities associated with subclinical hypothyroidism 
include an increased two to three fold risk for myocardial  infarction, left  ventricular 
diastolic  and  endothelial  dysfunction.  Left  ventricular  ejection  fraction  is  similar  to 
euthyroid state at rest, but reduced with exercise.
                       In terms of neuropsychiatric function, the results have been mixed, with 
some studies suggesting increased rates of anxiety, depression, or cognitive impairment 
in subclinical  hypothyroidism and some studies failed to show significant  difference 
between euthyroid and subclinical hypothyroidism groups.
                       Given the difficulty of diagnosing thyroid failure in the elderly based on 
clinical suspicion, it has been suggested that TSH tests be included in routine thyroid 
function screening in the geriatric population, but there is controversy about the clinical 
significance  of  detecting  and treating subclinical  hypothyroidism in the  elderly.  The 
efficacy  of  routine  TSH screening  in  the  general  elderly  population  is  questionable 
because  of  the  lack  of  evidence  from randomized  control  trials  demonstrating  that 
treatment of asymptomatic patients improves outcomes of subclinical hypothyroidism.
                        The purpose of this study was to estimate the prevalence of unrecognized 
subclinical hypothyroidism in elderly patients in a tertiary care setting. This study was 
also an attempt to acknowledge the associated factors of subclinical hypothyroidism.
AIM OF THE STUDY
1. To  estimate  the  prevalence  of  subclinical  hypothyroidism  in  elderly  patients 
attending Geriatric Outpatient Department (Tertiary care centre).
2. To study the relationship between subclinical hypothyroidism & coronary artery 
disease.
3. To study the association between subclinical hypothyroidism & lipid levels.
4. To study the correlation of subclinical hypothyroidism & cognitive decline. 
5. To study the association between subclinical hypothyroidism & depression.
REVIEW OF LITERATURE
THE THYROID GLAND
ANATOMY
                       Thyroid is a small butterfly- shaped gland located anterior to the trachea 
between the cricoid cartilage and the suprasternal notch. The normal thyroid gland is 12-
20 g in size, highly vascular and soft in consistency. Four parathyroid glands, which 
produce parathyroid hormone are located posterior to each pole of the thyroid.
                       The thyroid gland develops from the floor of the primitive pharynx during 
the third week of gestation. The developing gland migrates along the thyroglossal duct 
to reach its final location in neck. The thyroid gland consists of numerous spherical 
follicles composed of thyroid follicular cells that surround secreted colloid. The colloid 
is  a  proteinaceous  liquid  containing  large  amounts  of  thyroglobulin,  the  protein 
precursor of thyroid hormones.
PHYSIOLOGY
                       The hypothalamus secretes Thyrotropin Releasing Hormone (TRH) which 
stimulates  production  of  Thyroid  Stimulating  Hormone  (TSH)  from  the  anterior 
pituitary.  TSH  in  turn,  stimulates  synthesis  and  secretion  of  thyroxine  (T4)  and 
triiodothyronine (T3) from the thyroid. These thyroid hormones (T3&T4) feed back to 
inhibit TRH and TSH production. 
Hypothalamic-pituitary-thyroid gland axis 
                       This thyroid axis is a classic example of endocrine feedback loop. TRH is 
the major positive regulator of the axis and the “set point” of the axis is established by 
TSH.                                      
                       Thyroid hormones (T3&T4) are derived from thyroglobulin, a large 
iodinated  glycoprotein.  After  secretion  into  the  thyroid  follicle,  thyroglobulin  is 
iodinated  on  tyrosine  residues  that  are  subsequently  coupled  via  an  ether  linkage. 
Reuptake  of  thyroglobulin  into  the  thyroid  follicular  cell  allows  proteolysis  and the 
release of newly synthesised T3 & T4. The entire process is triggered by the action of 
TSH with TSH receptor situated on the membrane of thyroid follicular cell.
Thyroid hormones transport &metabolism
                       T4 is secreted from the thyroid gland in about 20 fold excess over T3. 
Both  hormones  are  bound  to  plasma  proteins,  including  thyroxine-binding  globulin 
(TBG),  transthyretin  (TTR)  and  albumin.  When  the  effects  of  the  various  binding 
proteins  are  combined,  approximately  99.98 % of  T4 and 99.7% of T3 are  protein-
bound.  T3 is less tightly bound than T4 and so the amount of unbound T3 is greater than 
unbound T4   in spite of less total T3 in the circulation.
                       T4 may be thought of as a precursor for the more potent T3. T4 is  
converted to T3 by the deiodinase enzymes (Type I, II, III) located in various tissues. 
Thyroid  hormones  (T3  &  T4)  bind  with  high  affinity  to  nuclear  thyroid  hormone 
receptors (TRs) which are expressed in most tissues. T3 is bound with 10 to 15 times 
greater affinity than T4, which explains its increased hormonal potency.
                       It is important to note that the homeostatic mechanisms that regulate the 
thyroid  axis  are  directed  toward  maintenance  of  normal  concentrations  of  unbound 
hormones.
Actions of thyroid hormones                    
                       It is likely that all cells in the body are targets for thyroid hormones.  
Thyroid  hormones  have  profound  effects  on  many  physiologic  processes  such  as 
development, growth and metabolism. 
Growth: 
                      Thyroid hormones are clearly necessary for normal growth as evidenced  
by the growth-retardation observed in thyroid deficiency. The growth-promoting effect 
of thyroid hormones is intimately intertwined with that of growth hormone (GH).
Metabolism: 
                      Thyroid hormones stimulate diverse metabolic activities (carbohydrate & 
lipid)  in  most  of  the  tissues,  leading  to  an  increase  in  basal  metabolic  rate.  One 
consequence  of  this  activity  is  to  increase  body  heat  production,  which result  from 
increased oxygen consumption and rates of ATP hydrolysis. By the way of analogy, the 
action of thyroid hormones is akin to blowing on a smouldering fire.              
Cardiovascular system: 
                      Thyroid hormones mimic ß-adrenergic actions like increasing heart rate, 
cardiac contractility and cardiac output. They also promote vasodilatation, which leads 
to enhanced blood flow to many organs.
Central nervous system:
                       Both decreased and increased concentrations of thyroid hormones lead to  
alterations in mental state. Too little thyroid hormone make the individual feel mentally 
sluggish, while too much induces anxiety and nervousness.
Reproductive system:
                       Normal reproductive behaviour and physiology is dependent on having 
essentially normal levels of thyroid hormone.
                       The thyroid hormones also play a vital role in water and electrolyte  
balance, bone demineralisation, immune regulation in the intestine and can also alter the 
actions of other hormones &drugs. 
AGEING CHANGES OF THYROID
                       The structural and functional changes of the thyroid gland that occur with 
ageing  are  controversial.  There  is  increased  nodularity,  fibrosis,  and  lymphocytic 
infiltration of the thyroid gland with ageing. Although the physiology of the pituitary-
thyroid axis is altered in the course of normal ageing of most individuals, the ability of 
the axis to respond to stress is unaltered and normal thyroid function is maintained over 
the lifespan.
                       As the age advances, several changes occur in the hypothalamic-pituitary 
gland axis  with respect  to thyroid function.  The secretory response of  TSH to TRH 
stimulation in ageing persons has been reported to be decreased to 38% of the values in 
young persons. This may be an adaptive mechanism to the reduced need for thyroid 
hormone in older population.
                       The serum TSH concentration has been either unchanged, lowered or 
increased with ageing in various reports. This may be explained by the heterogeneity of 
the populations studied. 
                       In a study of healthy centenarians (age range 100 – 110 years), the median 
serum TSH level was lower than that of older individuals (age range 65 – 80 years).  The 
median serum TSH levels drift  upwards very slowly with age, but remain in normal 
limits in the absence of disease. Lower TSH levels seen in institutionalised patients and 
in very advanced old age (>95 years) are probably due to illnesses.
                       TSH levels rise about 50% in the late evening before the onset of sleep.  
Sleep attenuates this nocturnal peak of TSH secretion and sleep deprivation exaggerates 
the nocturnal TSH secretion. The diurnal variation of TSH levels has been reported to be 
absent in elderly.
                       The rate of thyroxine (T4) production is decreased, but peripheral 
degradation of T4 is also reduced. This tends to maintain a constant serum concentration 
of T4 throughout life. The uptake of iodine by the thyroid gland is also reduced with 
ageing by more than 50% when compared with young adults.
                       Autoimmune damage to the thyroid increases with ageing and is 
associated with abnormally increased levels of circulating thyroid autoantibodies.
Human ageing and thyroid hormone economy
• ↓ peripheral degradation of  thyroid hormones
• ↓ total T4 production
• ↔ serum T4 concentration
• ↓ conversion of T4 to T3
• ↔↓ serum T3 concentration
• ↔ serum TBG concentration
• ↔ thyroid gland response to TSH 
• ↓ pituitary TSH secretory response to TRH 
• ↓ diurnal variation of  TSH
• ↓ thyroid iodide clearance
• ↔ basal metabolic rate ( corrected for metabolic cell mass )
        ↓   decreased
        ↔ unchanged
THYROID DISIORDERS
                       The thyroid disorders are broadly classified and grouped into 4 categories. 
They are
1. Hyperthyroidism
2. Hypothyroidism
3. Nodular thyroid disease
4. Thyroid neoplasms
                       The first two are due to the abnormalities in the production of thyroid  
hormones. Based on these abnormalities, the classification can be modified functionally 
as
• Hyperthyroidism
• Subclinical hyperthyroidism
• Hypothyroidism
• Subclinical hypothyroidism
                      The term ‘subclinical’ denotes the laboratory finding of these hormonal abnormalities 
with either absent or very minimal clinical findings of the corresponding overt disease.
Hormone changes in thyroid dysfunction
Hyperthyroidism
                TSH – undetectable    FT3, FT4 – increased
Subclinical hyperthyroidism
                TSH – undetectable    FT3, FT4 – normal
Hypothyroidism
                TSH – increased          FT3, FT4 – decreased
Subclinical hypothyroidism
                TSH – increased          FT3, FT4 – normal 
                       The hormone levels always do not satisfy the above mentioned pattern 
and thus complicating the diagnosis. The conditions include the secondary causes for 
either  hyper-  and hypo-  thyroidism, thyroid hormone resistance,  poor  compliance of 
patients with thyroxine replacement in hypothyroidism, transient stages of auto-immune 
thyroid disease and sick euthyroidism or non- thyroid illness.
Sick euthyroid syndrome
                       The term sick euthyroid syndrome or non- thyroid illness (NTI) refers to 
serum thyroid hormone concentrations secondary to the physiological stress of severe 
illness in the absence of underlying thyroid disease. The understanding of the effect of 
NTI  on  thyroid  function  tests  is  very  important  especially  in  the  elderly  who have 
multiple other comorbid illnesses. The changes depend on the severity of the illness and 
the period at which the test is undergone (during acute illness or in recovery period).
                       The most common hormone pattern (25% to 50%) in NTI is a decrease in  
total and unbound T3 levels and normal levels of T4 and TSH. In more severe illness, T4 
level also falls and the decreases in the thyroid hormone levels may be an adaptation to 
spare the patient from the catabolic effect of thyroid hormones during the periods of 
extreme stress. The severity of the illness correlates with the degree of fall in the serum 
T3 concentration. The low serum T4 state correlates with poor prognosis.
                       Fluctuation in the TSH level also creates a challenge in the interpretation  
of  thyroid  function  tests  in  sick  patients.  Serum TSH level  usually  remains  normal 
except in the patients receiving dopamine or glucocorticoids, which reduce serum TSH 
levels. During the recovery period TSH level remains normal. There is increased reverse 
T3 (rT3) level either due to increased production or impaired clearance as a consequence 
of the decreased 5`-deiodinase with illness.
                       Any severe illness can induce changes in thyroid hormone levels and this 
makes  the  diagnosis  of  NTI  challenging.  The  features  to  consider  include  previous 
history  of  thyroid  disease  and  thyroid  function  tests,  course  of  patient’s  illness, 
documentation of medications that affect thyroid function or hormone levels and the 
measurement of rT3 together with unbound thyroid hormones and TSH. The diagnosis 
of NTI is frequently presumptive and only the resolution of the test results with clinical 
recovery can clearly establish the disorder.
SUBCLINICAL HYPOTHYROIDISM
                     The term subclinical hypothyroidism was coined by Bastenie et al in 1967. 
Evered  and  colleagues  subsequently  described  a  similar  group  of  asymptomatic 
individuals in whom  conventional tests of thyroid function showed nothing abnormal 
but they were all found to have a raised serum thyrotropin concentration.
                       Since then, hundreds of articles have been published on this topic, but  
physicians are no closer to understanding whether this mild, usually asymptomatic form 
of hypothyroidism presents a clinical risk, requiring screening for detection and thyroid 
hormone treatment, or whether screening and therapy are unnecessary and possibly even 
counterproductive (Cooper DS; JAMA 2004). 
Definition 
                       Subclinical hypothyroidism is defined as a biochemical state characterised 
by serum  Thyroid  Stimulating  Hormone  (TSH)  concentration  above  the  statistically 
defined upper limit of the reference range when serum free T4 (FT4) concentration is 
within  its  reference  range in  the  presence  of  few or no  definitive  clinical  signs  or 
symptoms suggestive of hypothyroidism. 
                       Other causes of an elevated serum TSH must be excluded like recovery 
phase  of  sick  euthyroid  syndrome;  recent  adjustments  in  levothyroxine  dosage  with 
failure  to  reach  a  steady  state,  particularly  in  poorly  compliant  patients;  or  during 
recovery  from  destructive  thyroiditis,  including  post-viral  subacute  thyroiditis; 
untreated  primary  adrenal  insufficiency;  patients  receiving  recombinant  human TSH 
injections; thyroid hormone resistance syndrome and the presence of TSH antibodies 
leading to falsely elevated TSH levels.
Synonyms
                       This term subclinical hypothyroidism has been given a variety of other 
names. They include:
• Mild thyroid failure
• Compensated thyroid failure
• Early hypothyroidism
• Latent hypothyroidism
• Mild hypothyroidism
• Asymptomatic hypothyroidism
• Pre-clinical hypothyroidism
• Hidden hypothyroidism
                       Clinical features can be absent to very few suggestive of hypothyroidism 
and hence the term subclinical is being replaced in many parts of the world. Although 
the term subclinical hypothyroidism is widely used, mild hypothyroidism may be more 
appropriate.              
Prevalence
                      The prevalence of subclinical hypothyroidism in elderly has been reported 
to  range  from 5.9% to  35% depending  on  health  status,  patient  characteristics  and 
patient selection procedures.
                       The prevalence is age and gender dependant. It increases as the age 
advances and in females than males.  The classic Whickham survey in Great  Britain 
reported increasing prevalence of elevated TSH levels with age, upto 18% in women 
older than 74 years of age. In Colorado Health Fair study the prevalence of subclinical 
hypothyroidism is 19% in those aged older than 74 years. 
                        In a survey in United States, the prevalence of serum TSH elevation was  
8.5% in women and 4.4% in men older than age 55 years. In a study conducted by 
Bemben et al in Oklahoma, 14.6% of the women and 15.4% of the men had subclinical 
hypothyroidism in older  people greater than 60 years.  In a study conducted in King 
Abdulaziz  University,  Saudi  Arabia,  about  35% of  the  elderly  women  attended  the 
outpatient clinic had subclinical hypothyroidism.
Etiology 
                       Subclinical hypothyroidism is caused by the same disorders of the thyroid 
gland as those that  cause overt  hypothyroidism. The following table enumerates the 
causes of subclinical hypothyroidism.
  
Chief among these is chronic autoimmune thyroiditis (Hashimoto's disease), which is 
commonly associated with increased titers of antithyroid antibodies, such as antithyroid 
microsomal antibodies (antithyroid peroxidase) and antithyroglobulin antibodies. This 
disorder is suspected when thyroid enlargement is observed, but antithyroid antibodies 
may  also  be  associated  with  atrophy  of  the  thyroid  and  hypothyroidism.  Another 
common cause of hypothyroidism is the treatment of Graves' disease. Thyroid failure is 
most  common after  radioactive iodine treatment,  but  hypothyroidism may eventually 
occur in 5 to 25 percent of patients treated with surgery or antithyroid drugs.                
 A survey of endocrinology clinic patients revealed that 57% of patients 
aged  55  and  older  presenting  with  primary  hypothyroidism  carried  a  diagnosis  of 
autoimmune thyroiditis, while 32% carried a diagnosis of postsurgical hypothyroidism 
and 12% had a diagnosis of post-radioiodine hypothyroidism. Only 2% of the patients in 
this  referral  population  presented  with  documented  evidence  of  secondary 
hypothyroidism.    
 Less  common  causes  of  hypothyroidism 
include use of medications such as lithium and amiodarone. Pituitary failure is a cause 
of secondary hypothyroidism but since, in this circumstance, the TSH level is low rather 
than high (and thus the direct cause of the thyroid failure),  this condition cannot be 
diagnosed with certainty until thyroid hormone levels fall below normal, and subclinical 
hypothyroidism as usually defined would not be detected.
Pathophysiology
                        Serum TSH has a log-linear relationship with circulating thyroid 
hormone levels (a 2-fold change in free thyroxine will produce a 100-fold change in 
TSH). Thus, serum TSH measurement is the necessary test for diagnosis of mild thyroid 
failure when the peripheral thyroid hormone levels are within normal laboratory range. 
The individual range for peripheral thyroid hormones is narrower than the population 
reference laboratory range; therefore, a  slight reduction within the normal range will 
result in elevation of serum TSH above the normal range. 
                       One of the myths that surrounds subclinical hypothyroidism is that the 
laboratory profile of an elevated serum TSH and normal free  thyroid hormone levels 
really represents "compensated hypothyroidism." The reasoning behind this idea is that, 
since the circulating levels of thyroid hormones are within the normal range with only 
the  serum TSH being  elevated,  the  affected  subject  is  really  euthyroid because  the 
increased TSH is stimulating and driving the thyroid gland to produce normal thyroid 
hormone levels.
                       Certainly, elevated  serum TSH levels do stimulate even a diseased thyroid 
gland to produce and release more thyroid hormone. The clearance  kinetics of thyroid 
hormones and TSH from the circulation actually makes such a conclusion inescapable. 
Because the half-life of T4 is 7 days and that of T3 is 1 day, the serum TSH, which has a 
half-life of less than 1 hour, would certainly be expected to return  to normal if thyroid 
hormone  levels  were,  indeed,  normal  for that  individual.  An  elevated  TSH  in  an 
individual patient, thus, means that the circulating thyroid hormone concentrations are 
insufficient for maintaining routine functions.
Stages of thyroid gland failure
                       The phenomenon of thyroid gland failure is now recognised and can be 
divided into four stages. 
Stage a: The earliest form is identifiable only by a positive TRH test  and is represented 
by the state of a normal FT4 level accompanied by a TSH level slightly above a given 
individual’s set point, but within the population reference range.
Stage b: Further along the continuum of thyroid failure is that involve mild elevation of 
TSH (5–10 mIU/L) with normal FT4 level. 
Stage c: This stage has prominent elevation of TSH above 10 mIU/L with normal FT4 
level.  
Stage  d:  The  final  stage  of  this  continuum is  overt thyroid  gland  failure  or  overt 
hypothyroidism, which is defined by a low FT4 and an elevated TSH, usually  much 
higher than 10 mIU/L.
                       The stages a, b and c are usually subclinical, stage d is overt. Stage b and  
c looks similar but the subjects in these two groups exhibit dissimilar characteristics. 
Stage c can be treated like overt even when the manifestations are subclinical. 
                       The state of subclinical hypothyroidism may also be found  in at least five 
distinct situations:
1. mild unrecognized thyroid failure 
2. under treated overt hypothyroidism
3. over treated overt hyperthyroidism 
4. transient disturbances of the thyroid axis
5. Euthyroid outliers (this term will be applied to the  2.5% of individuals possessing 
TSH values above the 97.5 percentile of the euthyroid distribution).  
                       A treatment plan for subclinical hypothyroidism should rely on awareness 
of the underlying pathogenesis, because the five different clinical states clearly require 
separate therapeutic strategies.    
       
Course of subclinical hypothyroidism
                       The course of the patients who are found to have an elevated TSH level 
without other findings can be either of the three of the following: 
1. The TSH level will be normal if measured again several months later; we would 
then attribute the initial elevation to laboratory error or to an episode of silent 
thyroiditis with a transient hypothyroid phase. 
2.  Subclinical hypothyroidism remains unchanged.
3.  Progression to overt hypothyroidism occurs at a rate of about 5 percent per year 
in patients with raised TSH levels and detectable antithyroid antibodies. 
                              In selected cases (e.g., elderly patients with high titers of antithyroid  
antibodies), the risk of progression to overt disease may be closer to 20 percent per year.  
Consideration of these possible outcomes affects the decision about whether to treat or 
to observe without treatment.
                       Subclinical hypothyroidism represents an early stage of thyroid disease 
that will commonly progress to overt hypothyroidism. One study evaluated the natural 
history  of  mild  thyroid  failure in  154  female  patients  over  a  10-yr  period;  57% of 
patients continued to  have  mild  thyroid  failure,  34% of  patients  progressed to  overt 
hypothyroidism, and 9% of patients reverted to a normal  TSH level. How many of the 
9% had a transient form of thyroiditis is unclear.                     
             In a study in men and women older than 55 years with a mean follow-up  
of 32 months, the TSH level normalized in 52% of those with a serum TSH of less than 
10 mIU/L. A similar study that stratified subjects on the basis of anti-thyroid antibody 
levels  reported  that  80%  of  elderly  adults  with  mild  hypothyroidism  with  initial 
measured anti-microsomal antibody titers greater than 1:1,600 eventually progressed to 
develop overt hypothyroidism requiring treatment with thyroxine replacement therapy.
                        In the 20 year follow-up study of  patients  with subclinical 
hypothyroidism in the Whickham survey, the annual rate of thyroid failure was 4.3% in 
those with positive thyroid antibodies, as compared to 0.3% in thyroid antibody negative 
patients.
                       The strongest predictors of progression are the presence  of high titers of 
antithyroid antibodies, serum TSH values greater than 10 mIU/L, a history of radioiodine 
ablation  for  Graves’ disease,  a  history  of  external  radiation  therapy  for  nonthyroid 
malignancies,  chronic lithium or amiodarone treatment.
Clinical manifestations
Signs and Symptoms of Hypothyroidism
• Weakness
• Lethargy
• Fatigue 
• Dry skin 
• Coarse hair 
• Cold intolerance 
• Constipation 
• Weight gain 
• Muscle cramps 
• Edema of face and eyelids
• Nonpitting edema of legs 
• Hoarseness 
• Hearing loss 
• Menorrhagia 
• Slowing of return phase of reflexes (e.g., ankle jerk) 
• Bradycardia
                       The above mentioned clinical signs and symptoms of hypothyroidism 
manifest when the disease is fully developed. But even in the earliest (subclinical stage), 
one or more of these findings may occur. 
                       The Colorado Thyroid  Disease Prevalence Study measured serum TSH 
levels and conducted symptom surveys in over 25,000 state residents. Elevated serum 
TSH values were found in 8.9% of those who were not already on thyroid hormone 
therapy.  In  response  to  a  validated  survey  regarding symptoms  of  thyroid  hormone 
deficiency, the 2,336 subjects who were identified as having subclinical hypothyroidism 
significantly.
                                    The more often reported symptoms are dry skin (28%; P < 0.001), poor 
memory (24%; P < 0.001), slow thinking (22%; P < 0.001), muscle weakness (22%; P < 
0.001),  fatigue (18%;  P <  0.01), muscle cramps (17%;  P <  0.001),  cold intolerance 
(15%;  P < 0.001),  puffy  eyes  (12%;  P <  0.05),  constipation  (8%;  P < 0.05),  and 
hoarseness (7%; P < 0.05) than did euthyroid subjects.
                                      It is important to note that, when euthyroid subjects experienced a mean of 
12.1%  of  all  listed  symptoms,  overtly  hypothyroid subjects  had  16.6%  of  these 
symptoms (P < 0.05 vs. euthyroid group), and subjects with subclinical hypothyroidism 
reported an intermediate 13.7% of the symptoms (P < 0.05 vs. euthyroid group) (Fig. 2
). This suggests a "dosage effect" between levels of thyroid hormones and symptoms. 
                        Consistent with these findings, a Swiss study  involving 332 women with 
hypothyroidism reported that 24% of the 93 subjects with subclinical hypothyroidism 
exhibited typical symptoms of hypothyroidism. These studies suggest that some patients 
with subclinical hypothyroidism do indeed have clinical manifestations of mild thyroid 
failure. 
                        These studies also emphasize the difficulty in making the diagnosis of 
primary hypothyroidism using clinical symptoms alone; euthyroid subjects and patients 
with mild or overt hypothyroidism all had similar constellations  of symptoms. Despite 
statistical  significance  in  large  groups, it  can be  difficult  in  an individual  patient  to 
distinguish a euthyroid subject from one with either mild or overt thyroid disease.
Adverse outcomes of subclinical hypothyroidism
                       The possible physiologic effects of subclinical hypothyroidism include 
dyslipidemia,  cardiovascular  risk,  neurocognitive  effects,  and  other  non-specific 
symptoms of overt hypothyroidism.
 Dyslipidemia:
                        Dyslipidemia is commonly found in hypothyroidism and also in 
subclinical  hypothyroidism.  Treatment  of  the  thyroid  disorder  potentially  improves 
dyslipidemia and reduces risk for cardiovascular diseases. In the absence of significant 
symptoms  associated  with  subclinical  hypothyroidism,  dyslipidemia  may  be  a  key 
indicator of thyroid failure.
                                    Although the view that overt hypothyroidism causes secondary 
hyperlipidemia and  promotes  atherosclerosis  has  been  generally  accepted, studies 
examining  the  relationships  between  hyperlipidemia, atherosclerosis,  and  subclinical 
hypothyroidism have yielded less convincing results. Some cross-sectional observational 
surveys  note  a  higher  prevalence of  subclinical  hypothyroidism  in  hyperlipidemic 
patients,  whereas  others  show  that  subclinical  hypothyroidism  subjects  manifest 
moderately (mostly up to 10%) higher average total cholesterol than controls.
                        In patients with full-blown hypothyroidism, serum levels of triglycerides, 
total cholesterol and low-density lipoprotein (LDL) cholesterol are elevated. In patients 
with subclinical hypothyroidism, not surprisingly, the same changes are present but are 
less  marked  and  less  consistent.  This  pattern  of  lipid  abnormalities,  of  course,  is 
important  because it  is  a risk factor  for atherosclerotic cardiovascular  disease.  Some 
studies  have  shown a  decrease  in  LDL cholesterol  and total  cholesterol  levels  after 
treatment with levothyroxine.
                        Subclinical hypothyroidism does result in small increase in low density 
lipoprotein cholesterol and a decrease in high density lipoprotein, changes that enhance 
the risk for development of atherosclerosis and coronary artery disease. The influence of 
subclinical  hypothyroidism on lipids was directly  proportional  to the degree of  TSH 
elevation.  It has been estimated that an increase in the serum TSH level of 1  mIU/L is 
associated with a rise in the serum total cholesterol (TC) concentration of 0.09 mmol/L 
(3.5 mg/dl) in women and 0.16 mmol/L (6.2 mg/dl) in men.
                       The Whickham study observed that lipid levels were not associated with 
TSH  elevations  after  age  adjustment.  The  follow-up  Whickham  survey  found  no 
association between elevated serum TSH and increased risk of ischemic heart disease or 
dyslipidemia.
                        A large  cross-sectional survey of 3410 elderly subjects in Maryland noted 
significantly elevated LDL cholesterol in subjects with subclinical hypothyroidism, but 
only for those with TSH higher than 10 mIU/L;  no increased frequency of diagnosed 
atherosclerotic diseases was found in this entire cohort of SH subjects. A report from 
Rotterdam noted that subclinical hypothyroidism subjects actually had lower TC than 
controls,  but manifested  increased  atherosclerotic  vascular  disease, suggesting  that 
factors other than TC contribute to the increased risk of atherosclerosis, although LDL 
was not explicitly determined.  In a study conducted by Haralampos et al  in Greece, 
patients with subclinical hypothyroidism exhibited increased Lipoprotein a (Lp a) levels 
compared to euthyroid patients.
                       Thus  on considering the  conflicting  data  of  the  large-scale  
epidemiological surveys of Whickham, Maryland and Rotterdam with respect to thyroid 
dysfunction and lipid levels is still debatable.
Cardiovascular diseases:
                       The association between overt hypothyroidism and coronary heart disease 
has been repeatedly observed (Becker 1985). Less evident is the role of asymptomatic 
mild  elevation  of  TSH  (subclinical  hypothyroidism),  even  though  it  represents  the 
majority of patients with thyroid dysfunction. There is no clear confirmational data to 
date that subclinical hypothyroidism causes clinical heart disease. However, mild failure 
of  the thyroid gland,  as  evidenced solely by elevation of  serum TSH level,  may be 
associated with increased morbidity, particularly for cardiovascular disease and subtly 
decreased myocardial contractility.
                       In subclinical hypothyroidism both cardiac structures and function remain 
normal  at  rest,  but  impaired  ventricular  function  as  well  as  cardiovascular  and 
respiratory adaptation to effort may become unmasked during exercise. These changes 
are reversible when euthyroidism is restored. Subclinical hypothyroidism does result in 
small  increase  in  low density  lipoprotein  (LDL)  cholesterol  and  a  decrease  in  high 
density lipoprotein (HDL) cholesterol, changes that enhance the risk for development of 
atherosclerosis and coronary artery disease.
                       Flow-mediated vasodilatation, a marker of endothelial function, is  
significantly  impaired  in  subclinical  hypothyroidism,  and  decreased  heart  rate 
variability, a marker of autonomic activity, suggests hypofunctional abnormalities in the 
parasympathetic  nervous  system.  In  subjects  with  subclinical  hypothyroidism  after 
coronary revascularization, a trend toward higher rates of chest pain, dissection, and re-
occlusion has been noted.          
                       Studies have shown that patients with subclinical hypothyroidism have 
slowed  left  ventricular  relaxation  time,  increased  vascular  tone  at  rest,  and  left 
ventricular systolic dysfunction with exercise and impaired endothelial function. In one 
comprehensive study of exercise capacity, patients with subclinical hypothyroidism were 
shown to have significant impairment of exercise-related stroke volume, cardiac index, 
and maximal aortic flow velocity.       
                       A 20 year follow-up study of the  original Whickham Survey found no 
association  between  initial hypothyroidism,  raised  serum TSH  levels,  or  antithyroid 
antibodies and the development of coronary artery disease. In contrast,  a more recent 
report  from  the  Rotterdam  Study  concluded that  patients  with  subclinical 
hypothyroidism have a significantly increased prevalence of aortic atherosclerosis and 
myocardial infarctions.
                       A study done by Hak et al (2000) shown that subclinical hypothyroidism 
independently doubled relative risk of myocardial infarction in females. Several more 
recent meta-analyses of observational studies found an association between subclinical 
hypothyroidism and coronary artery disease.  
                       In the two new studies, thousands of patients in the U.S. and Australia  
agreed to be followed for a period of years, in an effort to evaluate the ability of various  
risk factors to predict subsequent disease. One of the lab tests measured at the beginning 
of these studies was the TSH level. Investigators in the U.S. study, the Health, Aging and 
Body Composition Study,  found that  patients  with elevated TSH levels  (at  least  4.5 
mIU/L) had a significantly higher risk of developing heart failure over the next 4 years 
than patients with normal TSH levels.  In the Australian study, the Brusselton Health 
Study, patients with elevated TSH levels had an increased risk of hospitalization or death 
from coronary artery disease. In both studies, the higher the TSH level, the higher the 
risk. The highest risk was seen in patients with TSH levels of 10.0 mIU/L or greater.  
Thus,  after  the  adjustment  for  multiple  known  coronary  artery disease  risk  factors, 
subclinical  hypothyroidism can  be  considered  as  an  independent  and  important  risk 
factor for myocardial infarction.
Psychiatric and cognitive dysfunction:
                       Cognitive dysfunction can result  from increased or decreased  
concentrations of thyroid hormones. Clinical and subclinical hypothyroidism in elderly 
adults  are  associated  with  decreased  cognitive  functioning,  especially  memory, 
visuospatial  organization,  attention,  and  reaction  time.  Mild  variations  of  thyroid 
function,  even within normal limits,  can have significant  consequences for  cognitive 
function in them. 
                      Different cognitive deficits possibly related to thyroid failure do not  
necessarily  follow  a  consistent  pattern,  and  L-thyroxine  treatment  may  not  always 
completely restore normal functioning in patients with hypothyroidism. There is little or 
no  consensus  in  the  literature  regarding  how  thyroid  function  is  associated  with 
cognitive performance in the elderly. Subclinical hypothyroidism may be a predisposing 
factor for cognitive impairment.
                      Cook et al reported that elderly patients with subclinical hypothyroidism  
performed more poorly than euthyroid individuals on measures of verbal recall as well 
as on the Mini-Mental State Examination but working memory and processing speed 
were unaffected. In contrast, three studies failed to find cognitive impairment associated 
with subclinical hypothyroidism. 
                      The possibility of reversing some aspects of the cognitive impairment 
associated with subclinical hypothyroidism has been demonstrated after treatment with 
L-thyroxine.  The  comprehensive  study  of  Del  Ser  Quijano  et  al  revealed  that  L-
thyroxine treatment was associated with significant improvements on multiple cognitive 
measures  including  attention,  memory,  verbal  fluency,  and  executive  functions 
compared to control participants.
                       The elderly may be more vulnerable to the cognitive effects of subclinical  
hypothyroidism than young adults, suggesting that diagnosis and treatment may protect 
the  aging  brain  from  cognitive  deterioration.  However,  it  is  not  yet  certain  that 
favourable results obtained with young adults are predictive of favourable responses in 
elderly. Furthermore, different cognitive functions probably have varying sensitivity to 
hormonal or metabolic changes and not all the cognitive defects related to thyroid failure 
are completely reversible with L-thyroxine therapy. 
                       DATA RELATED TO AGGRAVATION OF DEPRESSION, BIPOLAR 
DISORDER  AND  EFFECTS  ON  COGNITIVE  FUNCTION  HAVE  BEEN 
PRESENTED  IN  SUBJECTS  WITH  SUBCLINICAL  HYPOTHYROIDISM.  THE 
PAQUID SURVEY AND CORRELATES OF SUBCLINICAL HYPOTHYROIDISM 
IN ELDERLY COMMUNITY RESIDENTS  IN THE SOUTH WEST OF FRANCE 
FOUND  THAT  INCREASED  TSH  LEVELS  WERE  SIGNIFICANTLY LINKED 
WITH  FEMALE  SEX  AND  WITH  THE  PRESENCE  OF  SYMPTOMS  OF 
DEPRESSION BUT NOT WITH IMPAIRMENT OF COGNITIVE FUNCTION.
                       IN A STUDY OF HEALTH STATUS, MOOD AND COGNITION IN 
EXPERIMENTALLY INDUCED  SUBCLINICAL HYPOTHYROIDISM  BY M.  H. 
SAMUELS ET AL, WHEN SUBCLINICAL HYPOTHYROIDISM WAS INDUCED 
IN  LEVOTHYROXINE  TREATED  HYPOTHYROID  SUBJECTS,  MILD 
DECREMENTS IN HEALTH STATUS AND MOOD WAS ESTABLISHED. MORE 
IMPORTANTLY, THERE  WERE  INDEPENDENT DECREMENTS  IN  WORKING 
MEMORY,  WHICH  SUGGESTS THAT  SUBCLINICAL  HYPOTHYROIDISM 
SPECIFICALLY  IMPACTS  BRAIN  AREAS RESPONSIBLE  FOR  WORKING 
MEMORY.   
Neuromuscular function:
                        A variety of neuromuscular complaints have all  been reported to occur 
more frequently in patients with subclinical hypothyroidism. Objective peripheral nerve 
dysfunction, manifested by decreased conduction amplitude in peripheral nerves and an 
abnormal  stapedial  reflex  has  been  demonstrated  in these  patients.  Skeletal  muscle 
abnormalities,  including  elevated serum  creatine  phosphokinase  levels,  increased 
circulating lactate  levels  during  exercise  and  repetitive  discharges on  surface 
electromyography have also been reported.
Pulmonary function:
                        Pulmonary function in the patients with subclinical hypothyroidism 
revealed decreased vital capacity, reduced anaerobic threshold, and decreased oxygen 
uptake at the anaerobic threshold.
Iodine and subclinical hypothyroidism
                       Dietary iodine content appears to have an impact on the prevalence of 
hypothyroidism in the elderly.  A survey of  Chinese adults living in a  region of  low 
iodine  intake  revealed  that  only  1.0%  of  elderly  subjects  studied  met  criteria  for 
hypothyroidism, while a study of Eastern European nursing home residents revealed that 
subjects  living  in  regions  of  abundant  iodine  intake  had  six-fold  higher  rates  of 
hypothyroidism than  subjects  living in  regions  of  low iodine  intake.  These  findings 
suggest that iodine deficiency may have a protective effect against the development of 
hypothyroidism in the elderly.
                       In a study conducted in Andhra Pradesh,  India, by  Department of 
Biochemistry,  Kamineni  Institute  of  Medical  Sciences,  they  have  noticed  high 
prevalence of subclinical hypothyroidism in subjects consuming excessive amounts of 
iodine. In the present scenario of the post –iodination status in India, excessive iodine 
intake should also be considered as an etiology of hypothyroidism.
Screening
                       Despite recognition of this condition and the observation that a small 
percentage of  these patients advance to overt  hypothyroidism each year,  controversy 
continues  over  whether  elderly  individuals  should  be  screened  for  subclinical 
hypothyroidism.  The  decision  about  whether  to  screen  patients  for  this  disorder  is 
clouded by inconsistent evidence of any benefit from early treatment.
                       American Thyroid Association has endorsed screening for this disorder, 
but others, such as the US Preventive Services Task Force, have advised against routine 
screening.  In  addition,  although the American College  of  Physicians  recognises  that 
screening women older than 50 years for hypothyroidism may have some value, they 
specifically note that the benefit of treating patients with subclinical hypothyroidism has 
not  been  evaluated.  The  decision  about  whether  to  screen  patients  for  subclinical 
hypothyroidism is clouded by inconsistent evidence of any benefit from early treatment.
                      
Recommendations  of  eight  organisations  regarding  screening  of 
asymptomatic adults for thyroid dysfunction
    ORGANISATION                SCREENING RECOMMENDATION
1.American Thyroid                  Women and men > 35 yr of age should 
                   Association                                  be screened every 5 yr
2.         2.American Association of        Older patients, especially women  
En         Clinical  Endocrinologists                       should be screened
             3.College of American                 Women >50 yr of age should be screened 
              Pathologists                                if they seek  medical care ;  all geriatric
                                                                  patients should be screened on admission 
                                                                   & at least every 5 years
4.          4. American academy of               Patients >60 yr of age should be screened 
    Family physicians 
5. American college of               Women in ‘high risk groups’ should be 
 Obstetrics & Gynaecology            screened starting at 19 yr of age
6. American college of               Women >50 yr of age with an incidental
    Physicians                                 finding suggestive of symptomatic thyroid
The upper limit of serum TSH level
                       Lowering the upper limit of normal for the serum TSH level from 5.0 to 
3.0  or  even  2.5  mIU/L has  been  proposed,  but  such  proposals  have  been  met  with 
substantial  critique. The strongest  argument in favour of lowering the upper limit  of 
normal for the serum TSH level is the higher level of antithyroid antibodies detected in 
persons with a  serum TSH level  between 3.0 and 5.0 mIU/L and the higher rate of 
progression to clinical thyroid disease.
                      After exclusion of persons with goitre, antithyroid antibodies, and a family 
history  of  thyroid  disease,  the  mean  serum  TSH  is  1.5  mIU/L.  The  serum  TSH 
distribution curve is not Gaussian; there is a tail end at the upper limits of normal. If the 
distribution curve is extrapolated to be Gaussian, then the upper limit  for the 97.5th 
percentile will be 2.5 mIU/L.
                      The argument against lowering the upper limit of normal for TSH values is 
that  more  patients  would  be  diagnosed with hypothyroidism without  any clinical  or 
therapeutic benefit from this diagnosis. Decreasing the upper limit of the TSH reference 
range to 3.0 mIU/L results in more than a 4-fold increase in diagnosis of hypothyroidism 
among patients without history of thyroid disease seen in a tertiary medical centre. No 
clear evidence supports a benefit for intervening at these levels of TSH. 
                      Recent re-analysis of the data from the National Health and Nutrition 
Examination Survey III study has suggested that serum TSH distribution progressively 
shifts  toward  higher  concentrations  with  age  and  that  the  prevalence  of  subclinical 
hypothyroidism may be significantly overestimated in older age groups unless an age-
specific range for TSH is used. In a recent study of 766 persons with negative findings 
on  antithyroid  antibody  assay,  normal  findings  on  thyroid  ultrasonography,  and  no 
evidence of thyroid disease, Hamilton et al determined a serum TSH level of 4.1 mIU/L 
to be the upper reference limit. This value is more compatible with clinical experience 
and is a reasonable compromise.
                       The lack of evidence for a benefit from levothyroxine therapy at the level 
of 3.0 to 4.0 mIU/L makes keeping the upper limit of TSH at 4.0 to 5.0 (depending on 
the laboratory) more reasonable.
Treatment
                       There is considerable evidence suggesting that the subjects with 
subclinical hypothyroidism who would benefit most from L-thyroxine therapy are  those 
with TSH levels exceeding 10 mIU/L. Such individuals  constitute the minority of those 
with  subclinical  hypothyroidism in  all  large-scale epidemiological  studies  that  have 
stratified TSH levels. 
                      The majority of subjects with  subclinical hypothyroidism, however, have 
slight elevations of TSH ranging between 5 and 10 mIU/L, and they have minimal, often 
non-significant, metabolic  abnormalities.  They  are  either  affected  by  mild  incipient 
thyroid  failure  for  which  L-thyroxine  therapy  has  not  been  shown to  convey 
recognizable benefits, or they may simply represent "euthyroid outliers" in the 2.5% tail 
above the upper limit of the normal TSH reference range, in which case L-thyroxine 
treatment would be inappropriate.
                       Despite this, some  groups have recommended that all elderly patients with 
subclinical hypothyroidism and a TSH level  greater  than 10 mIU/L receive hormone 
replacement  therapy  (HRT)  and  that  HRT can  be  considered for  older  people  with 
compatible symptoms and a TSH level between 5 and 10 mIU/L. To date, no randomized 
controlled trials have provided evidence to support these recommendations, and there is 
reason to suspect that they may be flawed. 
                       From the animal  models of ageing, it is known that restriction in energy 
intake,  with its  associated reduction in metabolic  rate,  results in increased longevity. 
Administration of thyroid hormone could theoretically accelerate the ageing process by 
increasing metabolic rate.  In addition,  age-related hormone deficiencies (e.g.,  growth 
hormone) are not necessarily associated with poor outcomes. In fact, restoring hormone 
levels in older patients to those of younger patients may have adverse consequences.
                      For patients with sustained increases above 10 mIU/L, there is uniform  
agreement  that  thyroxine  therapy  is  indicated.  Therapy  for  milder  forms  of 
hypothyroidism is controversial. Some randomized clinical trials favour therapy for mild 
thyroid  failure,  but  they  are  inconclusive  because  they  lack  stratification  for  the 
subgroup of patients with TSH levels below 10 mIU/L. For this subgroup, individualized 
management is recommended. 
                       Recent studies have reported that "high normal" TSH values may  be 
associated with modest increases in serum cholesterol levels  and that serum cholesterol 
levels improve when TSH values are reduced from the high end to the low end of the 
normal range  with  L-thyroxine  supplementation.  In  patients  with  subclinical 
hypothyroidism and CAD, L-thyroxine therapy can be beneficial in diminishing lipid 
abnormalities in those with lower body mass index, briefer duration of CAD, and higher 
levels  of  cholesterol  at  baseline.  L-thyroxine treatment  appears to  have a preventive 
effect  on  the  disturbance  of  lipid  metabolism  in  patients  with  subclinical 
hypothyroidism, especially in patients with serum TSH levels above 10 mIU/L (Miura S, 
et al). 
                      A recent consensus statement issued by an expert panel recommended that 
cases of mild hypothyroidism presenting with TSH levels ranging from 4.5-10.0 mIU/L 
be  treated  on  a  provisional  basis,  with  continuation  of  therapy  predicated  on  clear 
evidence of improvement in symptoms consistent with thyroid hormone deficiency. 
                      Factors favouring L-thyroxine therapy in elderly patients with  TSH level 
of 5 to 10 mIU/L are:
                        1) Patient preference
                        2) Two TSH levels >8 mIU/L
                        3) Goitre
                        4) Bipolar disorder, depression
                        5) Presence of antithyroid antibodies
                        6) Convincing family history of              
                             thyroid disease
                        7) Severe hyperlipidemia not previously 
                             diagnosed                           
              8) Therapeutic trial for possible  
                      hypothyroid symptoms                                                                
                         9) Strong habit of tobacco use
                        10) Progressive TSH increase
An Algorithm for the Management of Subclinical Hypothyroidism
Levothyroxine therapy               
                        Patients with subclinical hypothyroidism, because of the minimal extent 
of  the  thyroid  hormone  deficiency,  may  be  controlled  with  total  daily  dosages  of 
levothyroxine as low as 25 to 50 µg. This initial dosage should be maintained for six to 
eight  weeks  before  a  TSH  measurement  is  repeated  to  guide  adjustment  of  the 
levothyroxine dosage. 
                         The goal is to maintain the TSH level within normal limits; the dosage of  
levothyroxine should be increased if the TSH level remains above normal and should be 
decreased if the TSH level falls below normal. Serum TSH should be checked after 8 
weeks  and the  dose  should  be  adjusted.  Once  a  normal  serum TSH level  has  been 
achieved, TSH should be measured again after 6 months and then annually. The benefits 
of fine-tuning levothyroxine therapy to achieve lower levels of serum TSH should be 
weighed against the possibility of adverse effects of overzealous levothyroxine therapy.
MATERIALS AND METHODOLOGY
Setting 
               Outpatient settings of Department of Geriatric Medicine, Government General 
Hospital, Chennai-3 (Tertiary care centre).
Study Design
               Cross-sectional study
Period of study 
               February 2009 to October 2009 (9 months)
Inclusion Criteria
      All patients attending Geriatric outpatient clinic during the   above mentioned 
period (maximum of 90 patients).
Exclusion criteria
1. Patients with recent surgery, recent myocardial infarction and with recent acute 
illness followed by hospitalisation in the past 6 months.
2. Patient who were already diagnosed to have any thyroid dysfunction (hypo- 
and hyper- thyroidism) or received radiotherapy over head and neck for any 
cause. 
Sample size
              A total of 90 patients were studied.
Details of the study
              All the 90 patients were randomly selected from the outpatient clinic of 
Department of Geriatric Medicine,  Government General  Hospital,  Chennai-3(Tertiary 
care centre). The patients divided into 3 age groups (60-69 years, 70-79 years, and 80+ 
years). 15 males &15 females were included in each age group.
                       All the study subjects were interviewed and the medical history was  
obtained. The patients were explained of the methods and objectives of the study and an 
informed consent was obtained from them. A brief general examination including height 
and  weight  measurement  was  carried  out  as  per  the  particulars  mentioned  in  the 
proforma.
Blood Pressure (BP):   Blood pressure was measured twice in the sitting position on the 
right arm, using standard mercury sphygmomanometer to the nearest 2 mm of mercury. 
 Coronary Artery Disease (CAD):   CAD was documented if the person had prior 
coronary  revascularization, coronary  angiographic  evidence  of  significant  CAD,  a 
documented history of myocardial infarction, electrocardiographic evidence of Q-wave 
myocardial infarction, or on treatment for CAD documented by cardiology department. 
All electrocardiograms were reviewed for evidence of myocardial infarction. 
Co-morbid illnesses:   Patients with only documented evidence of the co-morbidities 
like  Diabetes  Mellitus  (DM),  Systemic  Hypertension  (SHT),  Peripheral  Vascular 
Disease (PVD) and Cerebrovascular Accident (CVA) were taken into consideration.
Geriatric Depression Scale:  The original Geriatric Depression Scale was a 30- item 
questionnaire  which  was  time  consuming  and  challenging  for  both  patient  and  the 
examiner. Later versions retain only the most discriminating questions and their validity 
approaches that  of the original  form. The most  common version in general  geriatric 
practice currently is the 15 –item questionnaire. 
                      The test was undertaken orally. Patients were asked to reply indicating 
how they have felt  over the past  week. A clear yes or  no reply was obtained.  Each 
depressive answer (bold) was given a score of 1.
 Scoring intervals 
                               0-4     No depression
                               5-10   Mild depression 
                               11+    Severe depression 
Clock drawing Test & Mini-Cog:   Clock drawing test (CDT) is widely accepted and 
well validated screening tool for dementia. Their strength is in the brisk assessment of 
multiple  cognitive  domains  including  long-term  memory,  auditory  and  visual 
processing, motor planning, execution, etc. The patient was asked to draw a clock face 
showing a named time and then assessed. This has great value in ruling in or ruling out 
significant cognitive dysfunction.
                       The Mini- Cog test combines a 3- item recall test with a CDT. This is a  
sensitive and specific test, and largely uninfluenced by level of education, language or 
other cultural factors.
Administration
• The patient was asked to attend carefully and to remember three unrelated words 
(of the examiner’s choice) and then repeat the words to confirm registration.
• The patient was asked to draw a clock face on a blank sheet of paper showing a 
specific time. Instructions may be repeated, but no more detail given.
• The patient was asked to repeat the three words.
Scoring
• One point was given for each word correctly recalled after CDT.
• The CDT is normal if all numbers (1-12) were present in correct sequence and 
position.
Positive screen for dementia - score of 0 & 1 or 2 with an abnormal CDT.
Negative screen for dementia - score of 3 & 1 or 2 with normal CDT.
                    The patients were asked to come to the outpatient clinic on the next day  
morning with overnight fasting and around 5 ml of venous blood samples drawn were 
used  for  biochemical  laboratory  analysis.  The  laboratory  examinations  included 
estimation of Total  cholesterol,  High Density Lipoprotein (HDL), Triglycerides (TG) 
and Thyroid stimulating hormone (TSH) &free thyroxine (FT4).
Dyslipidemia:   Dyslipidemia was diagnosed if the serum total cholesterol was  200 
mg/dl, if the serum high-density lipoprotein (HDL) cholesterol was <40 mg/dl, or if the 
serum triglycerides was 200 mg/dl. 
Subclinical hypothyroidism:  Subclinical hypothyroidism was diagnosed if the serum 
TSH level was elevated and the serum T4 level was in the normal range.
Comparison between patients with subclinical hypothyroidism and without subclinical 
hypothyroidism was done with regard to symptoms, CAD, other co-morbities like DM, 
SHT, PVD, CVA, Depression, Dementia, as well as BMI and serum lipid values.
Statistical analysis
                     Statistical analysis was done using the Statistical Package for Social Sciences 
(SPSS). Independent T- test was done in all continuous variables. The chi-square test 
was used to analyse group difference for categorical variables. A p value of < 0.05 was 
considered significant. 
RESULTS
Prevalence
                  90 patients were studied and out of these 15 patients (16.7%) were found 
to have subclinical hypothyroidism.
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Prevalence in individual age groups
                  Of the 3 different age groups studied(60-69 yrs, 70-79 yrs, 80+), 
subclinical hypothyroidism was found in 4,5,6 patients in respective age groups and the 
others were  not found to have subclinical hypothyroidism.
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Sex Distribution
                 11 out of 45females (24.4%) and 4 out of 45 males (8.9%) had subclinical 
hypothyroidism.
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4  (8.9%)
34 (75.6%)
11 (24.4%)
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Gender Vs Subclinical hypothyroidism
No Yes
Sex and age group distribution
                        Among the 45 females studied, subclinical 
hypothyroidism was found in 3,3,5 patients in respective age groups of 60-69 yrs, 70-79 
yrs, 80+ yrs and the others were not found to have subclinical hypothyroidism.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Age 
Group
60 – 
69 
Years
12 (80.0%) 3 (20.0%)
0.963 0.618
(NS)70 – 79 12 (80.0%) 3 (20.0%)
Years
80+ 
Years 10 (66.7%) 5 (33.3%)
                          
                              Of the 45 males studied, 1,1,2 patients in respective age groups of 60-
69 yrs, 70-79 yrs, 80+ yrs were found to have subclinical hypothyroidism and not in the 
others. 
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
   Ag
e 
Group
60 – 69 
Years 14 (93.3%) 1 (6.7%)     0.549 0.760
( )NS
70 – 79 
Years 13 (86.7%) 2 (13.3%)
80+ Years 14 (93.3%) 1 (6.7%)
Symptom analysis
All subjects:
                        When the 10 common symptoms of hypothyroidism were studied in all  
the 90 subjects, no symptoms were acknowledged in 7(7.8%), 1 symptom in 21(23.3%), 
2  symptoms  in  33(36.7%),  3  symptoms  in  18(20.0%),  4  symptoms  in  7(7.8%),  6 
symptoms in 4(4.4%).
Symptoms Vs Subclinical hypothyroidism
              
                       When the same symptoms were studied in subjects with subclinical  
hypothyroidism, none of them had nil symptom (0%) , 3 had 1 symptom(20.0%), 8 had 
2 symptoms(53.3%), 2 had 3 symptoms(13.3%), 1 had 4 symptoms(6.7%) and 1 had 6 
symptoms(6.7%).
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Symptoms 
  10out of
No 
symptoms 7 (9.3%) 0 (0%)
     3.4
78
0.627
( )NS
1 
symptom 18 (24.0%) 3 (20.0%)
2 
symptoms 25 (33.3%) 8 (53.3%)
3 
symptoms 16 (21.3%) 2 (13.3%)
4 
symptoms 6 (8.0%) 1 (6.7%)
6 
symptoms 3 (4.0%) 1 (6.7%)
Coronary Artery Disease
                  Among the 90 subjects studied, 51(56.7%) did not have Coronary artery 
disease and 39(43.3%) had Coronary artery disease.
                   CAD
Number
 (n)
Percentage
(%)
  
No
51 56.7%
  
Yes
39 43.3%
Total 90 100%
51 (56.7%)
39 (43.3%)
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CAD Vs Subclinical hypothyroidism 
                        Among the 39 subjects who had Coronary artery disease, 27(69.2%) did  
not  have  subclinical  hypothyroidism and  12(30.8%) had  subclinical  hypothyroidism. 
Conversely, among the 15 subjects who had subclinical hypothyroidism, 3(20.0%) did 
not have Coronary artery disease and 12(80.0%) had Coronary artery disease.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Coronary 
Artery 
No 48 (94.1%) 3 (5.9%) 9.855 0.002
Yes 27 (69.2%) 12 (30.8%)
Disease ( )Sig
  = 7.11;            95%  (1.84 – 27.43)Odds ratio CI
48 (94.1%)
3 (5.9%)
27 (69.2%)
12 (30.8%)
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CAD Vs Subclinical hypothyroidism in females
                       Of the 11 females who had subclinical hypothyroidism, 8(72.7%) had 
Coronary artery disease and 3(27.3%) did not have Coronary artery disease.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Coronary 
Artery 
Disease
No 21 (61.8%) 3 (27.3%)
3.973 0.046
( )Sig
Yes 13 (38.2%) 8 (72.7%)
21 (61.8%)
3 (27.3%)
13 (38.2%)
8 (72.7%)
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CAD Vs Subclinical Hypothyroidism among 
females
No Yes
Comorbid illnesses
                       Among the 90 subjects studied, 29(32.2%) of them had no co-morbidity,  
41(45.6%) had single co-morbidity, 18(20.0%) had 2 co-morbities and 2(2.2%) had 3 
co-morbidities.
Co-morbidities Number
 (n)
Percentage
(%)
              -No co
morbidity
29 32.2%
             -One co
morbidity
41 45.6%
             -Two co
morbidities
18 20.0%
           -Three co
morbidities
2 2.2%
Total 90 100%
Comorbid illnesses Vs Subclinical hypothyroidism
                       Of the 15 subjects with subclinical hypothyroidism studied, 2 (13.3%) of  
them had nil, 7 (46.7%) had single co-morbidity, 5 (33.3%) had 2 co-morbities and 5 
(33.3%) had 3 co-morbidities.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Existing 
-co
morbidities
 -No co
morbidities 27 (36.0%) 2 (13.3%)
1 -co 34 (45.3%) 7 (46.7%)
morbidity
5.198 0.158
( )NS
2 -co
morbidities 13 (17.3%) 5 (33.3%)
3 -co
morbidities 1 (1.3%) 1 (6.7%)
Analysis 
of the co-morbidities
                      Of the co-morbidities, SHT was seen in 44(48.9%) patients and DM in 
25(27.8%) patients, CVA & PVD each in 7(7.8%) patients.
Diabetes mellitus Vs Subclinical hypothyroidism
                  Among the 15 patients with subclinical hypothyroidism, Diabetes mellitus 
was seen in 6(40.0%) patients.
Systemic Hypertension Vs Subclinical Hypothyroidism
                  Among the 15 patients with subclinical hypothyroidism, Systemic 
Hypertension was seen in 10(66.7%) patients.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Systemic 
Hypertension
No 41 (54.7%) 5 (33.3%) 2.227 0.131
( )NSYes 34 (45.3%) 10 (66.7%)
Depression
                       Among the 90subjects studied, 67(74.4%) were not depressed, 20(22.2%) 
had mild depression and 3(3.3%) had severe depression.
Age group Number
 (n)
Percentage
(%)
                  No 67 74.4%
                  Mild 20 22.2%
                  Sever
e
3 3.3%
  
Total
90 100%
67 (74.4%)
20 (22.2%)
3 (3.3%)
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Depression Vs Subclinical hypothyroidism
                       Of the 15 subjects with subclinical hypothyroidism, 11(73.3%) had no 
depression, 4(26.7%) had mild depression and none had severe depression.
Subclinical 
Hypothyroidism
Chi 
square 
P-
value
valueNon (%)
Yes
n (%)
 Depressio
 n
No 56 (74.7%)
11 
(73.3%)     0.76
3
0.683
( )NSMild 16 (21.3%) 4 (26.7%)
Severe 3 (4.0%) 0 (0%)
Depression Vs Subclinical hypothyroidism in females
                  Among the 11 females with subclinical hypothyroidism, 8 (72.7%) had no 
depression and 3 (27.3%) had mild depression and none had severe depression.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
 Depressio
  n
No 23 (67.6%) 8 (72.7%) 1.049 0.592
( )NSMild 8 (23.5%) 3 (27.3%)
Severe 3 (8.8%) 0 (0%)
Dementia
                    Among the 90 subjects studied, 79(87.8%) did not have dementia and 
11(12.2%) had dementia.
All Age groups Number
 (n)
Percentage
(%)
No 79 87.8%
Yes 11 12.2%
Total 90 100%
79 (87.8%)
11 (12.2%)
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Dementia Vs Subclinical hypothyroidism
                      Among the 15 subjects with subclinical hypothyroidism, 13(86.7%) had 
no dementia, 2 (13.3%) had dementia.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Dementia
No 66 (88.0%)
13 
(86.7%) 0.021 0.886
( )NSYes 9 (12.0%) 2 (13.3%)
Dementia Vs Subclinical hypothyroidism in females
                       Among the 11 females with subclinical hypothyroidism, 9(81.8%) had no 
dementia and 2(18.2%) had dementia.
Dyslipidemia
                    Among the 90 subjects studied, 51(56.7%) did not have dyslipidemia and 
39(43.3%) had dyslipidemia.
All Age groups Number
 (n)
Percentage
(%)
No 51 56.7%
Yes 39 43.3%
Total 90 100%
51 (56.7%)
39 (43.3%)
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Dyslipidemia
Dyslipidemia Vs Subclinical hypothyroidism
                       Among the 15 subjects with subclinical hypothyroidism, 13(86.7%) had  
dyslipidemia, 2(13.3%) had no dyslipidemia.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Dyslipidemia 
No 49 (65.3%) 2 (13.3%) 13.765 <0.001
( )SigYes 26 (34.7%)
13 
(86.7%)
  = 12.25;                95%  (2.57 – 58.46)Odds ratio CI
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2  (3.9%)
26 (66.6%)
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Dyslipidemia Vs Subclinical hypothyroidism in females
                  Among the 11 females with subclinical hypothyroidism, 9(81.8%) had 
dyslipidemia and 2(18.2%) had no dyslipidemia.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Dyslipidemia 
No 18 (52.9%) 2 (18.2%) 4.067 0.044
( )SigYes 16 (47.1%) 9 (81.8%)
     18(52.9%)
2(18.2%)
16(47.1%)
9(81.8%)
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Dyslipidemia Vs Subclinical hypothyroidism 
among females
No Yes
BMI (Body Mass Index)
                       Among the 90subjects studied, 13(14.4%) were under weight, 25(27.8%)  
were normal, 19(21.1%) were over weight and 33(36.7%) were obese.
All Age groups Number
 (n)
Percentage
(%)
  (<18.5)Under wt 13 14.4%
 (18.5 -Normal  
22.99)
25 27.8%
  (23.0 -Over wt  
24.99)
19 21.1%
 (Obesity ≥25.0) 33 36.7%
Total 90 100%
BMI Vs Subclinical hypothyroidism
                     Of the 15 subjects with subclinical hypothyroidism, 3(20.0%) were under 
weight, 1(6.7%) were normal, 4(26.7%) were over weight and 7(46.7%) were obese.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
 BMI
  (<18.5)Under wt 10 (13.3%) 3 (20.0%)
4.027 0.259
( )NS
 (18.5 -Normal  
22.99) 24 (32.0%) 1 (6.7%)
  (23.0 -Over wt  
24.99) 15 (20.0%) 4 (26.7%)
 (Obesity ≥25.0) 26 (34.7%) 7 (46.7%)
10  (13.3%
3 (20.0%) 24 (32.0%)
1 (6.7%)
15 (20.0%)
4 (26.7%)
26 (34.7%)
7 (46.7%)
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BMI Vs Subclinical hypothyroidism 
No Yes
BMI Vs Subclinical hypothyroidism in females
                  Among the 11 females with subclinical hypothyroidism, 3(27.3%) were 
under  weight,  0(0%)  were  normal,  3(27.3%)  were  over  weight  and  5(45.5%)  were 
obese.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
 BMI
  (<18.5)Under wt 2 (5.9%) 3 (27.3%)
6.754 0.080
( )NS
 (18.5 -Normal  
22.99) 9 (26.5%) 0 (0%)
  (23.0 -Over wt  
24.99) 6 (17.6%) 3 (27.3%)
 (Obesity ≥25.0) 17 (50.0%) 5 (45.5%)
BMI Vs Subclinical hypothyroidism in males
                  Among the 4 males with subclinical hypothyroidism, 0(0%) were under 
weight, 1(25.0%) were normal, 1(25.0%) were over weight and 2(50.0%) were obese.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
 BMI
  (<18.5)Under wt 8 (19.5%) 0 (0%)
2.106 0.551
( )NS
 (18.5 -Normal  
22.99) 15 (36.6%) 1 (25.0%)
  (23.0 -Over wt  
24.99) 9 (22.0%) 1 (25.0%)
 (Obesity ≥25.0) 9 (22.0%) 2 (50.0%)
CAD Vs Subclinical hypothyroidism in males
                        Of the 4 males who had subclinical hypothyroidism, all the 4(100%) had 
Coronary artery disease.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Coronary 
Artery 
Disease
No 27 (65.9%) 0 (0%)
6.585 0.010
( )Sig
Yes 14 (34.1%) 4 (100%)
Dyslipidemia Vs Subclinical hypothyroidism in males
                      Of the 4 males who had subclinical hypothyroidism, all the 4(100%) had 
dyslipidemia.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Dyslipidemia 
No 31 (75.6%) 0 (0%)
9.721 0.002
( )Sig
Yes 10 (24.4%) 4 (100%)
Depression Vs Subclinical hypothyroidism in males
                  Among the 4 males with subclinical hypothyroidism, 3(75.0%) had no 
depression and 1(25.0%) had mild depression and none (0%) had severe depression.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
n (%)
Depression 
No 33 (80.5%) 3 (75.0%)
0.069 0.793
( )NS
Mild 8 (19.5%) 1 (25.0%)
Severe 0 0 
Dementia Vs Subclinical hypothyroidism in males
                  Among the 4 males with subclinical hypothyroidism, all the 4 (100%) had 
no dementia.
Subclinical 
Hypothyroidism Chi square 
value
P-
valueNo
n (%)
Yes
N (%)
Dementia
No 35 (85.6%) 4 (100%) 0.675 0. 411
( )NSYes 6 (14.6%) 0 (0%)
DISCUSSION
                  Subclinical hypothyroidism is highly prevalent in elderly and more so in 
women.  The  prevalence  of  5.9% to  35% has  been documented  in  previous  studies, 
depending on health status, patient characteristics and patient selection procedures. It 
has  been  around  5.9%  of  an  unselected  population  of  community-dwelling  elderly 
persons  (Sawin  et  al)  and  in  9.6% and  14.6% of  institutionalized  elderly  men  and 
women, respectively. The prevalence of subclinical hypothyroidism was found in 6.8% 
of males and 13.8% of females (Mayer et al 2005).
                        Subclinical hypothyroidism was found in 11% of 1149 women, mean  age 
69  years,  participating  in  the  Rotterdam  Study.  Prevalence  of  hypothyroidism  was 
shown to gradually increase between age 45 and 60 years and to be higher in females, 
than in males (Canaris et al 2000;  Hollowell et al 2002). 35% of the elderly women 
attended the outpatient clinic had subclinical hypothyroidism in a study conducted in 
King Abdulaziz University, Saudi Arabia.
                       In this study of 90 elderly patients in a tertiary care setting, 15 patients (an 
over  all  prevalence  of  16.7%)  were  found  to  have  subclinical  hypothyroidism. The 
prevalence increased as the age advances in this study. The prevalence in 60-69 years 
age  group  was  13.3%;  the  prevalence  in  70-79  years  age  group  was  16.7%;  the 
prevalence in 80+ years age group was 20.0%. 11 out of 45 females (24.4%) and 4 out 
of 45 males (8.9%) had subclinical hypothyroidism. This finding is similar to that of 
other studies that reported a higher prevalence of subclinical hypothyroidism in elderly 
women compared with their male counterparts. The prevalence could have been much 
higher, if the patients with known thyroid dysfunction have also been included.
                       The rationale for identifying subclinical hypothyroidism in the elderly 
relates to its potential for progressing to overt hypothyroidism. In a longitudinal study of 
community-dwelling elders,  Rosenthal  et  al  found that  30% of elderly subjects  with 
elevated TSH levels developed overt hypothyroidism over a 4-year period. These studies 
indicate that TSH measurement in the elderly may provide important information about 
borderline thyroid function prior to complete thyroid failure.
                       Some studies have suggested that mild symptoms of hypothyroidism are 
more  prevalent  in  patients  with  subclinical  hypothyroidism  than  in  age-matched 
controls.   The "classic" clinical signs and symptoms of hypothyroidism are no more 
frequent  in  patients  with elevated TSH than in  the euthyroid elderly.  Thyroid status 
could  not  be  predicted  from clinical  signs  and  symptoms  in  this  sample  of  elderly 
community-dwelling patients (Bemben et al in 1994). 
                        In this study, 10 common symptoms of hypothyroidism were considered.  
29  out  of  90  patients  had  3  or  more  number  of  symptoms,  but  among  them only 
4(13.8%)  had  subclinical  hypothyroidism and  8  out  of  15  patients  with  subclinical 
hypothyroidism (53.3%) had 2 symptoms. The lack of a relationship between clinical 
symptoms and thyroid status was further evidenced by the inability of a high frequency 
of symptoms (≥3) to identify a higher proportion of subclinical hypothyroid patients 
diagnosed by elevated TSH levels.
                        The co-morbid illnesses like Diabetes mellitus, Systemic Hypertension, 
Peripheral vascular disease and Cerebrovascular accidents were also studied in these 90 
subjects. Systemic Hypertension was seen in 44 patients (48.9%) and Diabetes mellitus 
in  25  patients  (27.8%),  while  in  the  15  patients  with  subclinical  hypothyroidism, 
Systemic  Hypertension  was  seen  in  10  patients  (66.7%)  and  Diabetes  mellitus  in 
6(40.0%). Co-morbidities  typically  associated  with  hypothyroidism  were  no  more 
significantly prevalent in subclinical hypothyroid patients than in euthyroid patients.
                        The association of co-morbid illnesses could be further less in the  
community-dwelling  group because  the  patients  attending tertiary  care  centre  would 
have more ailments than this group. Hypertension is a well known accompanied fact 
with hypothyroidism and is needed to be studied in a large scale set-up to endorse its 
relationship with subclinical hypothyroidism.
                        A 20 year follow-up study of the  original Whickham Survey found no 
association between subclinical hypothyroidism and the development of coronary artery 
disease. An association between CAD and subclinical hypothyroidism has been reported 
in elderly women in the Rotterdam Study. In a study conducted in elderly women and in 
elderly  men  in  New  York  Medical  College,  Valhalla,  11%  of  CAD  patients  were 
associated  with subclinical  hypothyroidism. Analysis  of  the  relationship  between 
subclinical hypothyroidism and myocardial infarctions in The Rotterdam Study revealed 
an  attributable  risk  of  60%  (subclinical  hypothyroidism  contributed  to  60%  of  the 
myocardial infarctions in the women who had subclinical hypothyroidism).
                       In this study, among the 15 subjects with subclinical hypothyroidism,  
3(20.0%) did not have CAD and 12(80.0%) had CAD. Conversely, of the 39 subjects 
with  CAD,  12(30.8%)  had  subclinical  hypothyroidism  (p-value  0.002).  Of  the  11 
females with subclinical hypothyroidism, 8(72.7%) had CAD and 3(27.3%) did not have 
CAD  (p-value  0.046).  This  shows  a  significant  relationship  between  subclinical 
hypothyroidism and CAD.
                       In the above mentioned study conducted in New York Medical College, 
only  two  men  in  the  study  had  subclinical  hypothyroidism  and both  men  had 
electrocardiographic evidence of Q-wave myocardial infarction. In this study, of the 4 
males  with  subclinical  hypothyroidism,  all  the  4(100%)  had  CAD,  showing  a  very 
strong relationship between CAD and subclinical hypothyroidism. So, further evaluation 
is  needed and to  be performed with large  sample  size  to  support  the  association  of 
subclinical hypothyroidism with CAD in elderly men.
                       Thyroid Guide Mary Shomon point out that subclinical hypothyroidism is 
associated with metabolic syndrome. In this study among the 90 subjects, 13(14.4%) 
were under weight, 25(27.8%) were normal, 19(21.1%) were over weight and 33(36.7%) 
were obese.
                     Of the 15 subjects with subclinical hypothyroidism, 3 (20.0%) were under  
weight, 1(6.7%) were normal, 4(26.7%) were over weight and 7(46.7%) were obese (p-
value  0.259).  Though  there  is  no  significant  correlation  with  increase  in  BMI  and 
subclinical hypothyroidism, it is prudent to note that only 1 out of 15 (6.7%) subjects 
with subclinical hypothyroidism had normal BMI and all the others (93.3%) were either 
under-nourished or over- nourished.
                        IN A COMMUNITY-BASED CROSS-SECTIONAL SURVEY TO 
IDENTIFY THE SUBCLINICAL THYROID DYSFUNCTION AND ITS RELATION 
TO SOCIOECONOMIC DEPRIVATION IN THE ELDERLY BY SUE WILSON ET 
AL IN 2006, AN INDEPENDENT ASSOCIATION BETWEEN THE PREVALENCE 
OF  SUBCLINICAL  THYROID  DYSFUNCTION  AND DEPRIVATION  WHICH 
CANNOT BE EXPLAINED SOLELY BY THE GREATER BURDEN  OF CHRONIC 
DISEASE  AND/OR  CONSEQUENT  DRUG  THERAPIES  IN  THE  DEPRIVED 
POPULATION  HAS  BEEN  IDENTIFIED.  IT’S  A  RENOWN  FACT  THAT 
HYPOTHYROIDISM IS ASSOCIATED WITH OBESITY. SO, THE ASSOCIATION 
OF  NUTRITION  WITH  SUBCLINICAL  HYPOTHYROIDISM  IS  TO  BE 
ESTABLISHED IN NEAR FUTURE.                  
                       THE PAQUID SURVEY (1995)  AND CORRELATES OF 
SUBCLINICAL HYPOTHYROIDISM IN ELDERLY COMMUNITY RESIDENTS 
IN THE SOUTH WEST OF FRANCE FOUND THAT  INCREASED TSH LEVELS 
WERE  SIGNIFICANTLY LINKED  WITH  FEMALE  SEX  AND  WITH  THE 
PRESENCE OF SYMPTOMS OF DEPRESSION BUT NOT WITH IMPAIRMENT OF 
COGNITIVE FUNCTION.  PSYCHOLOGICAL SYMPTOMS  AND  QUALITY OF 
LIVING  (QOL)  WERE  WORSE  IN  SUBCLINICAL  HYPOTHYROIDISM 
(S.GULSEREN ET AL; 2008).
                        After the confounding effects of comorbid conditions and use of 
medications,  subclinical  thyroid  dysfunction  was  not  associated  with  depression, 
anxiety, or cognition (Lesley M. Roberts et al).  In this study among the 90 subjects 
studied, 67(74.4%) were not depressed, 20(22.2%) had mild depression and 3(3.3%) had 
severe depression. Of the 15 subjects with subclinical hypothyroidism, 11(73.3%) had 
no depression, 4(26.7%) had mild depression and none had severe depression (p-value 
0.683) failing to endorse the relationship of depression with subclinical hypothyroidism.
                      Among the 90 subjects studied, 79(87.8%) did not have dementia and 
11(12.2%)  had  dementia. Among  the  15  subjects  with  subclinical  hypothyroidism, 
13(86.7%)  had  no  dementia,  2  (13.3%)  had  dementia  (p-value  0.886).  Thus,  the 
association between dementia and subclinical hypothyroidism could not be established.
                       The Colorado Thyroid Disease Prevalence Study shown  the mean serum 
total  cholesterol  levels  in  the  22,842  euthyroid  subjects  (216  mg/dl),  the  2,336 
subclinical  hypothyroidism  subjects  (224  mg/dl),  and  the  114  subjects  with  overt 
hypothyroidism (251 mg/dl); both thyroid disease groups had statistically higher total 
cholesterol levels (data not shown) than did the euthyroid controls (P < 0.001).
                       In a study done to evaluate the serum lipid level alterations in subclinical 
hypothyroid  patients  in  Gorgan  by  Azad  Reza  Mansourian  et  al,  the  serum  total 
cholesterol concentrations were higher in subjects with subclinical hypothyroidism than 
in euthyroid subjects significantly.
                       In this study, among the 90 subjects studied, 51(56.7%) did not have 
dyslipidemia and 39(43.3%) had dyslipidemia and                      of the 15 subjects with 
subclinical  hypothyroidism,  13(86.7%)  had  dyslipidemia,  2  (13.3%)  had  no 
dyslipidemia (p-value<0.001). Among the 11 females with subclinical hypothyroidism, 9 
(81.8%) had dyslipidemia and 2 (18.2%) had no dyslipidemia (p-value 0.044). Of the 4 
males who had subclinical hypothyroidism, all the 4 had dyslipidemia (p-value 0.002). 
This  shows  a  significant  relationship  between  dyslipidemia  and  subclinical 
hypothyroidism both in elderly males and females. 
                       IN THIS STUDY, ALL THE MEN WITH SUBCLINICAL 
HYPOTHYROIDISM  WERE  FOUND  TO  HAVE  BOTH  CAD  AND 
DYSLIPIDEMIA. IN A STUDY OF RISK FOR ISCHEMIC HEART DISEASE AND 
ALL-CAUSE  MORTALITY  IN  SUBCLINICAL  HYPOTHYROIDISM  IN  JAPAN 
BETWEEN  1984  AND  1987  AND  FOLLOWED  BY  A 10  YEAR  FOLLOW-UP 
STUDY UNTIL 1998, INCREASED MORTALITIES FROM ALL CAUSES AFTER 
BASELINE MEASUREMENT WERE APPARENT IN MEN WITH SUBCLINICAL 
HYPOTHYROIDISM  (HAZARD RATIO,  1.9  TO  2.1)  BUT  NOT  IN  WOMEN, 
ALTHOUGH SPECIFIC CAUSES OF DEATH WERE NOT DETERMINED  (MISA 
IMAIZUMI ET AL). 
                       IN THIS JUNCTURE, IT IS TO BE EMPHASISED THAT LARGE-
SCALE  RANDOMISED,  PROSPECTIVE  CONTROLLED  STUDIES  WITH 
FOLLOW  UP  NEEDED  TO  BE  DONE  IN  ELDERLY  MEN  WITH 
SUBCLINICAL HYPOTHYROIDISM TO IDENTIFY THE CAUSAL ROLE OF 
SUBCLINICAL HYPOTHYROIDISM IN CORONARY ARTERY DISEASE AND 
DYSLIPIDEMIA.
CONCLUSION
          
 The prevalence of subclinical hypothyroidism is considerably high in this study 
(16.7%). The prevalence increases as the age advances. The prevalence is more in 
females than in males.
 Coronary  artery  disease  and  dyslipidemia  are  significantly  associated  with 
subclinical hypothyroidism.
 Body Mass Index shares a place in evaluation of subclinical hypothyroidism.
 There is a lack of relationship between clinical symptoms and the thyroid status in 
elderly. 
 The study failed to endorse the association of subclinical hypothyroidism with co-
morbid illnesses, depression and dementia.
 The cross-sectional nature of this analysis makes it difficult to ascribe causality to 
any  associations  found.  Because  we  do  not  know  whether  thyroid  test 
abnormalities preceded elevations in   lipid levels and coronary artery disease, it 
cannot be definitely stated that one leads to the other. Further evaluation of this 
relationship with longitudinal data would be necessary to support a causal link.
 The evaluation of  patients  from population-based screening programs who are 
found to have subclinical hypothyroidism rather than those referred for specialty 
management would be useful in determining the magnitude of the disease.
 The  thyroid  disease  should  be  considered  during  routine  evaluation  of  this 
susceptible group and should be followed by appropriate detection and treatment.
 Further research may determine whether treatment of subclinical hypothyroidism 
will benefit in preventing adverse health outcomes.
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                               PROFORMA
NAME:                                                                             ADDRESS:
AGE/SEX:
IP/OP/GM NO:
PREVIOUS OCCUPATION:
INCOME:                                                          PHONE/MOBILE NO:
SYMPTOMS:
     Fatigue                  Y/N                              Dry skin                     Y/N
       
     Weakness              Y/N                              Hair loss                     Y/N 
 
     Weight gain           Y/N Constipation            Y/N
     Edema Y/N Cold intolerance         Y/N
     Excessive sleep      Y/N                             Paraesthesia                Y/N
H/O intake of Antithyroid drugs        Y/N             H/O intake of Thyroxine      Y/N
Coronary artery disease        :  Y/N 
    
         If yes, then no. of years   :                        
                  
Other comorbid illness:
PVD        :        Y/N                                                        DM            :           Y/N 
CVA        :        Y/N                                                       SHT           :           Y/N
Height         :              cm                                    Weight     :            kg  
Pulse            :              /min                                  BP           :           mm/Hg  
ECG            :                                                     Ankle jerk :
GERIATRIC DEPRESSION SCALE
• Are you basically satisfied with your life?             Y/N 
• Have you dropped many of your activities and interests?            Y/N
• Do you feel that your life is empty?      Y/N
• Do you often get bored?      Y/N
• Are you in good spirits most of the time?      Y/N
• Are you afraid that something bad is going to happen to you?       Y/N
• Do you feel happy most of the time?       Y/N
• Do you often feel helpless?       Y/N
• Do you prefer to stay home, rather than going out and doing new things? Y/N
• Do you feel you have more problems with memory than most?      Y/N
• Do you think it is wonderful to be alive now?                                        Y/N
• Do you feel pretty worthless the way you are now?      Y/N
• Do you feel full of energy?      Y/N
• Do you feel that your situation is hopeless?      Y/N
• Do you think that most people are better off than you are?                     Y/N 
CDT & MINI-COG 
       Positive                           0/1 or 2 with aCDT
       Negative                         3/1 or 2 with nCDT
LIPID PROFILE:
Total cholesterol     :              mg/dl               LDL                    :              mg/dl 
Triglycerides          :              mg/dl               HDL                    :             mg/dl
THYROID PROFILE:
         TSH         :             μIU/ml                      FT4            :              ng/dl
ABBREVIATIONS
TSH Thyroid stimulating hormone 
FT4 Free  Thyroxine 
FT3 Free  Triiodothyronine
TRH Thyrotropin Releasing Hormone 
TBG Thyroxine-binding globulin 
TTR Transthyretin
TR Thyroid hormone receptors 
rT3 reverse T3 
NTI Non- thyroid illness 
Lp a Lipoprotein a 
TC Total cholesterol
HDL High Density Lipoprotein 
LDL Low-density lipoprotein
TG Triglycerides 
CAD Coronary Artery Disease
DM Diabetes Mellitus 
SHT Systemic Hypertension
 PVD Peripheral Vascular Disease 
CVA Cerebrovascular Accident 
CDT Clock drawing test 
BMI Body Mass Index
SYMP Number of Symptoms
NS Not Significant
Sig Significant  
yrs years
GDS Geriatric Depression Scale

